Mark Baum, Harrow CEO
Harrow prices $60M offering one day after acquiring US, Canadian rights to new dry eye treatment
Eye biotech Harrow Health is looking to raise $60 million after buying the rights to an eye product newly approved by the FDA.
The company …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
